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Background: Total arterial grafting is increasingly preferred in coronary artery
bypass grafting, but it increases blood loss. Aprotinin (Trasylol; Bayer Corp,
Leverkusen, Germany) reduces blood loss in cardiac surgery but has not been
subjected to a randomized trial in total arterial grafting.
Methods: A single-center, randomized, double blind, placebo-controlled trial of
aprotinin administration in total arterial grafting was performed. The primary
outcome variable was postoperative blood loss, and the secondary outcome variable
was the number of units of donor blood or coagulant products transfused. The
incidence of myocardial injury was determined from serial measurements of cardiac
troponin T and creatine kinase-MB and renal injury from serum creatinine.
Results: The placebo group (n 34) and aprotinin group (n 36) were similar with
respect to all preoperative and intraoperative comparisons. One patient in each
group underwent reexploration for bleeding. Open-label aprotinin was administered
to 9 patients in the placebo group (26%) and to 2 patients in the aprotinin group
(6%). There was a highly significant reduction in the median (interquartile range)
blood loss in the aprotinin group compared with the placebo group (785 mL
[590-1025 mL] vs 1525 mL [1175-1920 mL], respectively). Similarly, the aprotinin
group demonstrated a marked reduction in the need for blood transfusion (77% vs
39%; P .0001), the mean number of transfused blood units (2.6 vs 0.8, P .001),
and the number of patients requiring coagulant products (24% vs 3%; P  .001).
There was no difference in myocardial injury in the 2 groups. Four patients in the
aprotinin group had persistently elevated creatinine levels in the postoperative
period (3 of whom had elevated preoperative creatinine levels and perioperative
complications).
Conclusions: Aprotinin significantly reduces blood loss and the need for blood
component transfusion in patients undergoing total arterial grafting without increas-
ing the risk of myocardial injury. Aprotinin should be considered routinely in
patients undergoing total arterial grafting but cautiously in patients with an elevated
preoperative creatinine level.
There is a growing trend toward complete arterial revascularization inpatients undergoing coronary artery bypass grafting (CABG). Theclinical and survival benefits of a single internal thoracic artery(SITA) graft are well recognized, and current studies suggest addi-tional benefits of bilateral ITA (BITA) grafts.1 In a meta-analysis ofthe best observational studies of SITA and BITA grafts, we recently
reported that BITA grafts offer survival advantages over SITA grafts.2 For total
arterial grafting (TAG), the radial artery is now commonly used as the third arterial
graft.3
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It is the principal investigator’s standard practice to per-
form CABG using BITA and radial artery grafts. However,
in my experience (D.P.T.),4 the use of BITA grafts increases
mean postoperative blood loss by approximately 400 mL in
comparison with the use of a SITA graft (mean [SD] BITA
vs SITA: 1324 mL [362 mL] vs 945 mL [330 mL]; P 
.01). This is consistent with an increased surface area of
chest wall dissection when harvesting BITA vessels.
Aprotinin is a naturally occurring serine protease inhib-
itor that has potent hemostatic properties when used in
cardiac surgery. Recent advances in the understanding of
the basic mechanism of aprotinin have shown that aprotinin
may in fact also have antithrombotic properties by its se-
lective blockade of protease-activated receptor-1 thrombin
receptors.5
The major concern over the routine use of aprotinin is,
however, an increased risk of graft occlusion and perioper-
ative myocardial infarction (MI) through prothrombotic
mechanisms. The International Multicenter Aprotinin Graft
Patency Experience (IMAGE) trial was undertaken to re-
solve conflicting conclusions of studies that documented an
increased risk of vein graft occlusion6-8 and those that did
not.9 The IMAGE trial was conducted in 13 centers in the
United States and Europe, randomizing 870 patients to
aprotinin or placebo and assessing the graft patency using
graft angiography.10 Unfortunately, whereas vein graft oc-
clusion rates were similar in the 2 American groups (9%),
they differed in the European groups (23% in the aprotinin
group vs 12% in the placebo group). Even after adjustment
for risk factors, the IMAGE trial suggested that aprotinin led
to a slightly increased risk of venous graft occlusion when
evaluated on per-patient or per-graft analysis.
We hypothesized that aprotinin would be efficacious in
reducing blood loss in patients undergoing TAG without
increasing the risk of myocardial injury, particularly be-
cause arterial grafts are inherently more resistant to throm-
bosis than vein grafts. Consequently, we performed a ran-
domized trial of aprotinin in patients undergoing TAG to
determine blood loss and need for blood products. The
incidence of perioperative MI and myocardial injury was
assessed by serial electrocardiograms and measurements of
cardiac troponin T (cTnT) and creatine kinase (CK)-MB.




The Central Oxford Research Ethics Committee approved the trial
(C00.019), which was conducted in accordance with Good Clinical
Practice for Trials on Medicinal Products in the European Com-
munity (July 1990). To ensure compliance with these guidelines,
the study was monitored and open to audit by Bayer and an
independent body.
Patient Information and Consent
Consenting patients, fulfilling the inclusion and violating none of
the exclusion criteria, provided written informed consent before
participation.
Power Calculations
The sample size calculation was based on the primary efficacy
variable and postoperative blood loss, and aimed to detect a
difference between the aprotinin and placebo groups. From previ-
ous studies, blood loss seemed to have a log-normal distribution,
so calculations were based on the geometric mean and SD. A
placebo geometric mean of 1223.6 mL and geometric SD of 1.5
mL was assumed. Converting this to loge scale, this became 7.110
mL and 0.432 mL, respectively. The power was set at 90%, and a
2-sided significance level was set at 5%, with a clinically relevant
difference of 30% reduction in the geometric mean postoperative
blood loss in the active group. Thirty-two evaluable patients were
therefore required in each treatment group. Allowing for an inval-
idity rate of 15%, a total sample size of 75 patients was required.
Patients
Eligible patients were those undergoing first-time isolated CABG
who required at least 2 bypass grafts in which it was planned that
revascularization would be performed only using arterial conduits.
Patients could be undergoing elective or urgent, but not emergency
(ie, immediate), surgery. Exclusion criteria were significantly im-
paired left ventricular function (ejection fraction estimated
25%), acute MI within 6 weeks, known or suspected allergy to
aprotinin, possible previous exposure to aprotinin, coagulopathy or
history of any bleeding diathesis, and use of any investigational
drug within the previous 30 days. Patients could be withdrawn at
any time for medical reasons, for example, excessive postoperative
bleeding necessitating resternotomy. For patients who prematurely
discontinued participation in the trial, a final assessment was
completed, wherever possible, according to the schedule of the
120-hour visit.
Overall Study Design and Plan
The study was a single-center, double-blind, parallel group, pla-
cebo-controlled comparison of patients undergoing total arterial
revascularization conducted by a single surgeon.
Randomization
A predetermined randomization scheme was generated by the
Biometry Department of Bayer, using a fixed block size. Patients
were risk stratified as elective or urgent. Sealed code break cards
were available for clinical reasons.
Drug Dose
Patients were randomized 1 day before surgery to receive placebo
or full-dose (“Hammersmith”) aprotinin infusion, commenced af-
ter induction of anesthesia. After induction of anesthesia, and
before sternotomy, a test dose (5.0 mL of 1.4 mg/mL or 10,000
kallikrein inactivation unit/mL) of aprotinin or placebo solution
was administered over several minutes through the central line. If
there was no evidence of hypersensitivity after 10 minutes, the
remaining 195 mL of the loading dose was administered over 20 to
30 minutes using an infusion pump. After completion of the
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loading dose, a maintenance infusion of 50 mL/h was continued
for 4 hours. A further 200 mL was added to the pump prime of the
bypass circuit.
Anesthetic Protocol
Patients were premedicated with papaveretum and hyoscine. An-
esthesia was induced using a combination of fentanyl and etomi-
date and maintained with nitrous oxide/air and halothane or isoflu-
rane. Anesthesia was maintained on cardiopulmonary bypass
(CPB) with a propofol infusion. Antibiotic prophylaxis was gen-
tamicin and flucloxacillin or cefuroxime.
Cardiopulmonary Bypass
The bypass circuit was primed with 1.5 L Hartmann’s solution,
and a membrane oxygenator was used. Flow rates were maintained
to achieve 2.4 L/m2, and the patient’s temperature allowed to
decrease to 34°C. Continuous flow and alpha-stat control of acid
base balance was used. Perfusion pressures were maintained be-
tween 40 and 90 mm Hg, with vasoconstrictor or vasodilator
agents as necessary.
Anticoagulation on Bypass
Prolongation of the activated clotting time (ACT) by aprotinin can
lead to an overestimation of the degree of anticoagulation, leading
to inadequate anticoagulation. Consequently, a kaolin-activated
ACT greater than 600 seconds of heparin was obtained before
institution of CPB with a loading dose of 300 U/kg of heparin. The
ACT was rechecked periodically on CPB, and further heparin was
administered if the ACT decreased less than 600 seconds. Heparin
was reversed with 1 mg of protamine per 100 units of heparin, and
additional protamine was administered depending on the measured
ACT.
Transfusion Policy
Doctors and nurses, independent of the trial, determined the
routine postoperative management of the trial patients. If any
patient experienced excessive postoperative bleeding (blood
loss of 200 mL in the first 2 consecutive hours in patients who
were otherwise stable and in whom the bleeding was expected
to stop without need for rethoracotomy), then, at the discretion
of the investigator, double-blind medication was stopped, and
an open-label aprotinin infusion started according to routine
clinical practice.
In general terms, hemostatic factors were requested when
bleeding was approximately 200 mL/h in otherwise stable patients.
During the preoperative and postoperative periods, blood was
transfused if the hemoglobin decreased to less than or was equal to
9 g/dL. Further units were administered to ensure that hemoglobin
was maintained greater than 9 g/dL.
Analysis
The study was analyzed on an intention-to-treat (ITT) basis and
included those patients who received open-label aprotinin. All
patients receiving trial treatment were included in the safety anal-
ysis.
Trial Objectives
The primary aim of the trial was to assess the efficacy of aprotinin
in reducing postoperative blood loss after TAG and the need for
transfusion of blood and blood products. In addition, the frequency
of resternotomy, time to extubation, and total duration of hospital
stay was recorded. Myocardial injury was assessed by serial elec-
trocardiographic changes and serum CK-MB and cTnT (calculated
as an area under the curve [AUC] from serial measurements) and
renal function by measurement of serum creatinine.
Statistical Analyses
Summary statistics for the demographic data include the arithmetic
mean and SD (normally distributed data), the geometric mean and
SD (log-normally distributed data), and the median and range
(non-normal data) or frequency counts (categoric data, in which
the number of categories were small).
Treatment groups were compared at baseline to check for
balance in prognostic factors using the Student 2-sample t test
(normally distributed variables), Wilcoxon 2-sample test (non-
normally distributed variables), and Fisher’s exact test (categoric
variables).
The primary efficacy parameter, postoperative blood loss, was
tested for normality using the Shapiro-Wilk test, and because it
was approximately normally distributed after applying log trans-
formation, the treatment groups were compared using the Student
2-sample t test.
Because the number of units of donor blood and other blood
products and the frequency of resternotomy were categoric, non-
normal data, the Wilcoxon 2-sample test was used to compare
treatment groups, and the Cochrane-Mantel-Haenszel test was
used when the number of categories was small. The number of
patients receiving a blood transfusion at any time during the study
was summarized using frequency counts and percentages, and
treatment groups were compared using Fisher’s exact test.
For cTnT and CK-MB, the AUC was computed for each
patient. By providing an integrated value for the release of a
chemical or metabolite over a given time frame, the AUC increases
the chances of detecting minor differences between 2 groups while
minimizing the chances of a false-positive finding by making
multiple comparisons of individual time points. Furthermore, the
AUC allows comparison of the data from all patients in a trial,
including those with minor elevations in any chemical or metab-
olite, even when they remain within the normal range.
The AUC was calculated over 8 time points from the preop-
eration baseline (0 hours) to 123 hours after baseline by using the
trapezoidal rule with interpolation for missing intermediate time
points and then dividing by 123 to give units in nanograms per
milliliter. Where a measurement at the final time point was miss-
ing, the AUC was calculated over the time points present and then
divided by the appropriate time interval to give units in nanograms
per milliliter. The AUC data for cTnT and CK-MB were compared
between the 2 treatment groups using the Wilcoxon 2-sample test.
Results
Patients
Between April 2000 and April 2001, 74 patients in total
were randomized in this double-blind, parallel group,
placebo-controlled, single-center study (Table 1). Seventy
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patients were available for an analysis on an ITT basis, 34
in the placebo group and 36 in the aprotinin group (Table 1).
In the placebo group, 3 patients were not available for ITT
analyses (1 was withdrawn before receiving trial treatment,
1 had randomization code broken, and 1 received disal-
lowed concomitant medication). In the aprotinin group, 1
patient was withdrawn before receiving trial treatment.
Protocol deviations, which did not exclude patients from
the ITT analyses, are summarized in Table 1. Of particular
note, open-label aprotinin was administered to 9 patients in
the placebo group (26%) and to 2 patients in the aprotinin
group (6%), and venous conduit was used in 4 patients in
the placebo group (12%) and in 2 patients in the aprotinin
group (6%).
Demographic Features
The groups were similar with respect to age, gender, height,
weight, and urgency of operation (Table 2). In both groups,
approximately one third of patients underwent urgent oper-
ation for unstable angina and 15% of all patients were
treated for diabetes.
Intraoperative Data
The groups were similar with respect to overall operative
time and number of distal anastomoses (Table 3). Never-
theless, the mean crossclamp time was 6 minutes longer in
the placebo group compared with the aprotinin group (54
[12] vs 48 [12] minutes, respectively; P  .01).
Postoperative Blood Loss and Transfusion
Requirements
There was a highly significant reduction in the median
(interquartile range) blood loss in the aprotinin group com-
pared with the placebo group (785 [590-1025] vs 1525
[1175-1920], respectively) (Table 4). One reason for an
apparently high blood loss in the placebo group is that one
third of these patients were urgent cases, and many would
have been taking aspirin and clopidogrel. The need for red
blood cell transfusion was reduced from 77% in the placebo
group to 39% in the aprotinin group (P  .0001). Overall,
the mean number of transfused red blood cell units was 0.8
in the aprotinin group and 2.6 in the placebo group. Simi-
larly, there was a highly significant reduction in the need for
coagulation products in the aprotinin group. A single patient
(3%) in the aprotinin group required coagulant products in
contrast with 24% of patients in the placebo group.
Secondary Clinical Outcomes
One patient in each group underwent reexploration for
bleeding. There was no difference in time to extubation or
time to drain removal in the 2 groups (Table 5). The median
TABLE 2. Summary of demographic data
Placebo Aprotinin P
Age (mean, SD) 61 (8) 60 (8) .6
Percent male 94% 92% 1.00
Height in centimeters (mean, SD) 174 (8) 171 (8) .06
Weight in kilograms (mean, SD) 83 (11) 83 (12) .9
Diabetes mellitus (types I and II) 5 (14%) 6 (16%) .9
Percent elective admission 68% 67% 1.00
Percent urgent admission 32% 33%
TABLE 3. Summary of intraoperative data
Placebo Aprotinin P
Number 34 36
Duration of operation in
hours (mean, SD)
3.1 (0.5) 3.1 (0.6) .7





2 4 (12%) 7 (19%) .56
3 20 (59%) 22 (61%)
4 9 (27%) 7 (19%)
5 1 (3%) 0
Duration of crossclamp
in minutes (mean, SD)
54 (12) 48 (12) .01
TABLE 1. Withdrawals and protocol deviations in intention-to-treat analyses
Placebo Aprotinin
Randomization 37 37
Withdrawal No medication 1 1
Randomization code broken 1
Randomization code broken and disallowed medication 1
Included in intention-to-treat analyses 34 36
Protocol deviations Received venous conduit 1 1
Received open-label aprotinin 5 1
Venous conduit and open-label aprotinin 1 1
Coagulopathic drug and open-label aprotinin 1
Venous conduit, coagulopathic drug, open-label aprotinin 1
Received anticoagulant drug preoperative 2 2
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duration of high dependency unit and postoperative hospital
stay was 1 and 6 days, respectively, in both groups.
Biochemical Data
Serial data for cTnT and CK-MB release are presented in
Figures 1 and 2. cTnT and CK-MB AUCs were calculated
over 8 time points from preoperation baseline (0 hours) to
the fifth postoperative day (123 hours) dividing by 123 to
give units in nanograms per milliliter. For cTnT, the respec-
tive AUC (median and IQ range) was 0.15 (0.08-0.22) in the
placebo group and 0.12 (0.08-0.18) in the aprotinin group (P
 .40). For CK-MB, the respective AUC (median and IQ
range) was 6.0 (2.4-12.8) in the placebo group and 4.8
(3.5-8.2) in the aprotinin group (P  .64).
Electrocardiographic Criteria
Perioperative MI (defined as the appearance of new q waves
or loss of 20% R waves with cTnT  2.0 ng/mL and
CK-MB 100 ng/mL) occurred in 2 patients (3%; 1 in each
group).
Renal Injury
Serial changes in serum creatinine in both groups are pre-
sented in Figure 3. Overall, there was no significant differ-
ence between the groups. There were, however, 4 patients in
the aprotinin group and 2 patients in the control group
whose postoperative creatinine exceeded 2 mg/L on day 5.
Of particular interest, 3 of these 4 patients in the aprotinin
group had elevated preoperative creatinine levels (1.7, 1.7,
1.5 mg/L, respectively), whereas both the control patients
had normal preoperative creatinine values. In addition, the 4
patients in the aprotinin group had other complications that
may have contributed to renal impairment, namely, long-
standing type I diabetes mellitus, severe prolonged postop-
erative ileus, perioperative MI, and “prophylactic” intra-
aortic balloon pump insertion for severely impaired left
ventricle function. In the control group, 1 patient had no
obvious explanation for a precipitous increase in postoper-
ative creatinine, whereas the other patient had a hypovole-
mic cardiac arrest when a clip on the stump of the proximal
right ITA eroded into the subclavian artery requiring emer-
gency reexploration.
Discussion
There is growing evidence that TAG, and in particular the
use of BITA grafts, offers survival and other clinical ad-
vantages over a single ITA graft and supplemental vein
grafts.1,2 Inasmuch as we had previously reported that the
use of BITA grafts increases postoperative blood loss, the
routine use of aprotinin seemed persuasive, especially be-
cause arterial grafts are inherently more resistant to throm-
bosis than vein grafts. To our knowledge, this is the first
randomized trial of aprotinin in patients undergoing TAG.
Potential Limitations of this Trial
Although this was a trial of TAG, 4 patients in the placebo
group (12%) and 2 patients in the aprotinin group (6%)
received additional vein grafts. This reflected our “learning”
phase with TAG and now occurs in less than 5% of our
patients. In any event, it did not affect the results of the trial
when analyzed on an ITT basis.
TABLE 5. Secondary clinical outcomes
Placebo Aprotinin P
Number 34 36
Reexploration for bleeding 1 (3%) 1 (3%) 1.00
Hours to extubation in hours
(median, 95% CI)
8 (6-27) 23 (7-26) .34
Hours to thoracic drains
removal (median, 95% CI)
29 (27-41) 26 (22-28) .06
Days in high dependency unit
(median, IQ range)
1 (0.9-1.2) 1 (0.9-1.1) .81
Postoperative days in hospital
(median, IQ range)
6 (6-7) 6 (6-7) .84
CI, Confidence interval.
TABLE 4. Postoperative blood loss and transfusion requirements
Placebo (34) Aprotinin (36) P
Total postoperative blood loss in milliliters
(median and interquartile range)
1525 (1175–1920)mL 785 (590–1025)mL .0001
Requirement for red blood cell transfusion
Percent of patients requiring blood transfusion 77% 39% .0001
Number of transfused units 0 8 (24%) 22 (61%)
1 5 (15%) 7 (19%)
2-4 15 (44%) 6 (17%)
5 or  6 (18%) 1 (3%)
Requirement for coagulant products
Fresh frozen plasma 8 (24%) 1 (3%)
Platelets 7 (21%) 1 (3%)
Cryoprecipitate 1 (3%) 0
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Blood Loss, Blood Transfusion, and Use of
Coagulation Products
This trial demonstrates that aprotinin results in a dramatic
reduction in blood loss and blood product requirements in
patients undergoing TAG. Aprotinin almost halves blood
loss, halves the number of patients requiring red blood cell
transfusion, and significantly reduces the number of units
transfused per patient and the need for coagulant products.
Even so, our results may still underestimate the benefits of
aprotinin; in the ITT analyses, 26% of patients in the pla-
cebo group received open-label aprotinin compared with
6% of patients in the aprotinin group.
Aprotinin and Risk of Myocardial Injury
The overall AUC for both troponin and CK-MB release,
reflecting a global index of myocardial injury, was lower in
the aprotinin group, although this did not reach statistical
significance.
There is conflicting evidence as to whether aprotinin
increases the risk of perioperative myocardial injury in
conventional CABG using an ITA and vein grafts. Cos-
grove and colleagues6 reported an increased incidence of
perioperative MI in patients undergoing redo CABG from
7% of patients (4/56) in the placebo group to 16% of
patients (9/57) receiving high-dose aprotinin. Lemmer and
coworkers7 also reported an increased risk of perioperative
MI in patients receiving high-dose aprotinin (8.9% vs
5.6%), although this did not reach statistical significance. In
contrast, the IMAGE study assessed 831 patients’ electro-
cardiograms and cardiac enzymes and reported that aproti-
nin did not increase the risk of MI compared with the
placebo group.10 Similarly, a multicenter study of redo
CABG by Alderman and colleagues11 showed no difference
in the incidence of MI in the placebo or aprotinin-treated
groups (29%). These conflicting observations may be ex-
plained, in part, by the meta-analysis of 72 trials involving
more than 8000 patients performed by Levi and col-
leagues.12 They reported that high-dose, but not low-dose,
aprotinin increased the risk of perioperative MI.
It must be emphasized that these studies did not in-
clude patients undergoing TAG. Consequently, a second-
ary aim of our trial was to assess the effect of aprotinin
on both MI and global injury. Perioperative MI (suggest-
ing focal injury) was determined by a combination of
serial electrocardiograms and cardiac-specific enzymes
(cTnT, CK-MB), whereas global myocardial ischemia
was determined from an integrated AUC for total enzyme
release calculated from serial enzyme measurements at 8
time points over 5 days.
Our trial demonstrates that aprotinin does not increase
the risk of perioperative myocardial injury in the setting of
TAG. It is notable, however, that only 2 patients (3%)
experienced a perioperative MI, according to electrocardio-
graphic and biochemical criteria. Because most periopera-
tive MIs are caused by acute graft failure,8 it is possible that
this may represent a reduced risk of acute failure of arterial
conduits in comparison with vein grafts. This is certainly
consistent with angiographic data from several studies re-
porting significantly better patency of arterial conduits in
comparison with vein grafts early after CABG,13 but in the
absence of our own angiographic data this must remain
speculative.
This is also consistent with various animal studies that
have shown aprotinin to be cardioprotective particularly
when used as a cardioplegia additive.
Aprotinin and Risk of Renal Injury
Although several studies have reported that aprotinin does
not increase the risk of renal failure after cardiac surgery,14
others have documented an increase in postoperative serum
creatinine levels. In a multicenter, randomized study of 212
patients undergoing valve replacement, postoperative in-
creases in creatinine exceeding 0.5 mg/dL occurred in 30%,
14%, and 8% of the high-dose aprotinin, low-dose aproti-
nin, and placebo groups, respectively, and were statistically
significantly different.15 In a randomized study by Cosgrove
and associates,6 postoperative increases in serum creatinine
of greater than 0.5 mg/dL occurred in 25%, 20%, and 18%
in the high-dose aprotinin, low-dose aprotinin, and placebo
groups, respectively, although these differences were not
statistically significant. Similarly, a multicenter, random-
ized, controlled trial showed a modest postoperative in-
crease in serum creatinine levels in 19% of the patients
(20/108) in the aprotinin group compared with 12% of the
patients (13/108) in the placebo group, although this was not
statistically significant.14
Overall, as judged by median and interquartile ranges,
our trial did not show any adverse effect of aprotinin on
renal function as judged by serial serum creatinine levels.
This is consistent with the recent trial by Schweizer and
colleagues,16 who randomized 57 patients undergoing car-
diac surgery with CPB to high-dose aprotinin and placebo
and detected no difference in several sophisticated param-
eters of renal function between the groups. It should be
noted, however, that 4 patients in the aprotinin group and 2
patients in the control group had postoperative creatinine
levels exceeding 2 mg/L on day 5. In the control group, 1
patient had a hypovolemic cardiac arrest requiring emer-
gency thoracotomy to control bleeding, and the other patient
had no obvious explanation for the precipitous increase in
creatinine. Of the 4 patients in the aprotinin group, 3 had
elevated preoperative creatinine levels, and 4 had other
complications that may have contributed to postoperative
renal impairment. It is therefore uncertain whether it was the
elevated preoperative creatinine level or a perioperative
complication that contributed most to the postoperative
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Figure 1. TnT in the 2 groups (median and interquartile range [box]; spread of the data [whiskers]).
Figure 2. CK-MB in the 2 groups (median and interquartile range [box]; spread of the data [whiskers]).
Figure 3. Serum creatinine in the 2 groups (median and interquartile range [box]; spread of the data [whiskers]).
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elevation, but it would seem sensible to use aprotinin cau-
tiously in those with preoperative renal impairment.
Conclusion
This trial demonstrates that aprotinin results in a dramatic
reduction in blood loss and blood product requirements in
patients undergoing TAG without increasing the risk of
myocardial injury. Aprotinin should be used more cau-
tiously in those with preoperative renal impairment.
D.T. conceived the study, designed the protocol, performed all
the operations, and wrote the main draft of the article. V.D.
performed literature searches and assisted in drafting the manu-
script. M.N. assisted in the daily conduct of the study as well as
collecting blood samples. A.D. enrolled patients and was respon-
sible for drug administration and collection of blood samples. Dr
Mark Summery and Dr Edward Tucker provided particular assis-
tance in the design of the protocol and in ensuring the smooth
running of the trial.
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